Schweitzer PK, Strohl KP, Mayer G, et al. - In subgroups of participants with obstructive sleep apnea (OSA) who were adherent or nonadherent to primary OSA therapy at baseline, researchers aimed at evaluating the effectiveness of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, as well as the effect of solriamfetol on the use of primary therapy in an open-label extension trial. Solriamfetol 75, 150, or 300 mg/d was provided for ≤ 52 weeks to participants with OSA who completed prior solriamfetol studies. Adherent (n = 255) and nonadherent (n = 78) subgroups had mean Epworth Sleepiness Scale scores of 15.0 and 15.8 at baseline (of 12-week study) and 6.5 and 6.8 at week 40, respectively. Outcomes revealed similar long-term effectiveness and safety of solriamfetol regardless of adherence to primary OSA therapy. No effect of solriamfetol on primary therapy use was noted.